Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1035-8. doi: 10.1080/15257770.2011.622732.


We have retrospectively evaluated the uric acid control status and renal function changes over a period of up to 7 years in 35 patients with renal impairment who had stage 3 or higher chronic kidney disease (CKD; stage 3 in 32 patients, stage 4 in 2 patients, and stage 5 in 1 patient) associated with hyperuricemia and were receiving monotherapy with benzbromarone as an antihyperuricemic drug. Serum uric acid levels significantly decreased from 8.5 ± 0.9 to 6.1 ± 0.8 mg/dL at 6 months and were subsequently controlled at less than 7.0 mg/dL in most patients. Most patients received benzbromarone at a dose of 25-50 mg/day, whereas 150-200 mg/day was used in some patients with stage 4 or 5 CKD. No significant changes in estimated glomerular filtration rate (eGFR) from the baseline value of 46.2 ± 11.5 mL/minute/1.73 m(2) were found after benzbromarone therapy. Although the renal function impairment did not improve by reducing the serum uric acid levels with benzbromarone, the renal function did not deteriorate further on the therapy. These results suggest that benzbromarone is applicable to the management of hyperuricemia associated with renal impairment.

MeSH terms

  • Benzbromarone / pharmacology
  • Benzbromarone / therapeutic use*
  • Female
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Hyperuricemia / blood
  • Hyperuricemia / complications*
  • Hyperuricemia / drug therapy*
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / drug therapy*
  • Male
  • Middle Aged
  • Treatment Outcome
  • Uric Acid / blood
  • Uricosuric Agents / pharmacology
  • Uricosuric Agents / therapeutic use*


  • Uricosuric Agents
  • Uric Acid
  • Benzbromarone